Clinical trials: Antipsychotic
Schizophrenia
A Trial to Assess the Antipsychotic Efficacy of ITI-007
The study will be conducted as a randomized, double-blind, parallel-group, placebo-controlled, multi-center study in patients diagnosed with schizophrenia having an acute exacerbation of psychosis.
- Trial name
- NCT02282761
- Testing
- ITI-007
- Where
- 11 sites in United States
- Volunteers
- 450 people
- Sponsor
- Intra-Cellular Therapies, Inc.
Schizophrenia, Schizoaffective Disorder
Clinical Estradiol Trial in Women With Schizophrenia
To investigate the 'estrogen-protection' hypothesis by comparing changes in psychotic symptoms between one group of patients receiving standard antipsychotic drug treatment plus placebo and a second matched group receiving…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
- Trial name
- NCT00206570
- Testing
- Estradiol
- Where
- Australia
- Volunteers
- 100 people
- Sponsor
- Bayside Health
Schizophrenia
Neurobiological and Neurocognitive Disturbances in First-episode Schizophrenia
We want to relate disturbances in first-episode schizophrenic patients in serotonin 5-HT2A receptors, brain structure, brain function, and information processing to each other and to psychopathology.
- Trial name
- NCT00207064
- Testing
- quetiapine
- Where
- 3 sites in Denmark
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Birte Glenthoj
Psychotic Disorders, Metabolic Syndrome x
Is Health Coaching Effective for Improving Metabolic Health in People With Psychosis Disorders?
Antipsychotic medications frequently cause metabolic side-effects, such as abdominal obesity, high blood pressure, cholesterol abnormalities, and blood sugar dysregulation, all of which can lead to what is known as the Metabolic…
- Trial name
- NCT01752465
- Testing
- Health Coaching, Standard care
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- University of British Columbia
Combat Disorders, Stress Disorders, Post-Traumatic
Quetiapine Augmentation for Treatment-resistant PTSD
The purpose of this study is to compare the response of veterans with PTSD without an optimal response to paroxetine to quetiapine augmentation versus placebo.
- Trial name
- NCT00292370
- Testing
- Open Label (OL) Paroxetine, Quetiapine
- Where
- 3 sites in United States
- Volunteers
- 124 people
- Sponsor
- VA Office of Research and Development
Borderline Personality Disorder
Quetiapine Treatment for Symptoms Associated With Borderline Personality Disorder
Objective: The objective of this study is to quantitatively examine the efficacy of Seroquel (active ingredient quetiapine fumarate) in subjects with Borderline Personality Disorder (BPD).
- Trial name
- NCT00122070
- Testing
- Quetiapine Fumarate
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- University of Medicine and Dentistry of New Jersey
Bipolar Disorder, Schizophrenia
Antipsychotics and Blood Vessel Function
Over the last decade, second generation antipsychotics have been increasingly utilized. Since their introduction, however, atypical antipsychotics have been increasingly associated with significant metabolic complications…
- Trial name
- NCT00585273
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- Jess G. Fiedorowicz
Schizophrenia and Disorders With Psychotic Features
Antipsychotic Effects of Sorghum Bicolor (JOBELYN) in the Treatment of Schizophrenia
Sorghum bicolor is a naturally growing plant which has been of health benefit to the people of West Africa who traditionally prepare its leaf for various nutritional and health reasons.The food and nutritional fact analysis…
- Trial name
- NCT02240173
- Testing
- Jobelyn, Haloperidol
- Where
- Nigeria
- Volunteers
- 100 people
- Sponsor
- Federal Neuro-Psychiatric Hospital, Yaba
Schizophrenia
Demographic and Clinical Predictors of Persistence in Patients Treated With Aripiprazole Once-monthly in Italy
This is an observational, retrospective, non-interventional study that will include schizophrenic patients who were initiated with aripiprazole once-monthly as per normal clinical practice at least 6 months before the data…
- Trial name
- DOMINO (NCT03005769)
- Where
- 20 sites in Italy
- Volunteers
- 262 people
- Sponsor
- Otsuka Pharmaceutical Europe Ltd
Antipsychotic-induced Weight Gain (AIWG)
A Study to Assess the Safety, Efficacy, and Pharmacokinetics of Miricorilant (CORT118335) in Obese Adults With Schizophrenia or Bipolar Disorder Treated With Antipsychotic Medications
This phase 2, double blind, placebo-controlled, randomized study is to assess the safety, efficacy, and pharmacokinetics (PK) of miricorilant (CORT118335) in obese adults with schizophrenia or bipolar disorder treated with…
- Trial name
- GRATITUDE (NCT03818256)
- Testing
- Miricorilant
- Where
- 27 sites in United States
- Volunteers
- 71 people
- Sponsor
- Corcept Therapeutics
Schizophrenia, Psychotic Disorders
A Study of the Effectiveness and Safety of Risperidone in the Treatment of Adolescents With Schizophrenia
The purpose of the study is to assess the safety and effectiveness of risperidone (an antipsychotic medication) in adolescents with schizophrenia over 6 months of treatment.
- Trial name
- NCT00246285
- Testing
- risperidone
- Volunteers
- 381 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Normal Non-fluency
Effect of Short Term Atypical Antipsychotic Administration Compared to Placebo on Hepatic Insulin Extraction
Within the past 20 years, there has been a striking increase in the incidence of obesity 1;2, type 2 diabetes mellitus (T2DM) 3-5, and cardiovascular diseases (CVD) in the schizophrenic population 6-8 .
- Trial name
- NCT02447835
- Testing
- Olanzapine
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Michael Rickels
Schizophrenia
A Study to Compare Two Different Brain Imaging Techniques in Healthy Volunteers and in Schizophrenic Patients
A direct comparison of Positron Emission Tomography (PET) (11C-Raclopride) and Single Photon Emission Computed Tomography (SPECT) (123I-IBZM) D2 RO measurements would allow GSK to gain understanding on the SPECT results obtained…
- Trial name
- NCT00392743
- Testing
- pet/spect scan
- Where
- 7 sites in Spain
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Weight Loss, Diabetes Mellitus, Type 2
Reducing Weight and Diabetes Risk in an Underserved Population (STRIDE)
The purpose of this study is to examine the effectiveness of a lifestyle intervention designed to reduce weight and diabetes risk in a population of individuals with mental illness who are also taking antipsychotic medications.
- Conditions
- Weight Loss, Diabetes Mellitus, Type 2, Psychotic Disorders
- Trial name
- STRIDE (NCT00790517)
- Testing
- Premier Lifestyle Intervention with DASH Diet
- Where
- 3 sites in United States
- Volunteers
- 200 people
- Sponsor
- Kaiser Permanente
Schizophrenia
Do Antipsychotic Agents Induce Supersensitivity in Humans: A Combined PET/MRI Study in Patients With Schizophrenia
The aim of the present study is to detect changes in the dopamine system in the brain of patients with schizophrenia, especially when pretreated with antipsychotic medication.
- Trial name
- NCT03911726
- Testing
- Single PET/MR-measurement
- Where
- Germany
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- Central Institute of Mental Health, Mannheim
Schizophrenia, Psychotic Disorders
Relative Bioavailability of LY03010 Compared to Listed Drug
This is a randomized, multiple-dose, open-label, parallel-group study. Subjects will undergo screening evaluations to determine eligibility within 28 days prior to study drug administration.
- Conditions
- Schizophrenia, Psychotic Disorders, Mood Disorders, Schizophrenia Spectrum
- Trial name
- NCT04922593
- Testing
- LY03010; paliperidone palmitate, INVEGA SUSTENNA
- Where
- 9 sites in United States
- Volunteers
- 281 people, healthy volunteers welcome
- Sponsor
- Luye Pharma Group Ltd.
Schizophrenia
Transcutaneous Non-invasive Vagus Nerve Stimulation (t-VNS) in the Treatment of Schizophrenia
Randomized, controlled, double-blind, two-armed clinical investigation to show the efficacy and safety of transcutaneous vagus nerve stimulation (t-VNS), applied at the left auricle, in schizophrenia.
- Trial name
- 02VNS2009 (NCT01176721)
- Testing
- t-VNS verum
- Where
- 2 sites in Germany
- Volunteers
- 20 people
- Sponsor
- cerbomed GmbH
Schizophrenia
Antipsychotic Polypharmacy: Prevalence, Background and Consequences
The primary purpose of the study is to investigate whether an intensive educational intervention can reduce the use of antipsychotic polypharmacy.
- Trial name
- NCT00541398
- Testing
- Implementation of guideline
- Where
- Denmark
- Volunteers
- 222 people
- Sponsor
- Glostrup University Hospital, Copenhagen
Schizophrenia
Evaluation of Effectiveness and Safety of Paliperidone ER (Extended-release) Compared With Quetiapine in Patients With Schizophrenia
The purpose of this study is to evaluate the efficacy (effectiveness of drug) and safety of the antipsychotic paliperidone ER compared to another antipsychotic, quetiapine, and to placebo in patients who are acutely ill with…
- Trial name
- NCT00334126
- Volunteers
- 399 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Bipolar Disorder, Schizoaffective Disorder
Comparison of Combination Olanzapine+Lithium or Chlorpromazine+Lithium in Treatment of First Manic Episode With Psychotic Features
Aim: In a population of first episode manic patients with psychotic features, we want to compare the side effect profile, the degree of adherence and the subjective well being, as well as the efficacy of two treatments: The…
- Trial name
- NCT00202293
- Testing
- Olanzapine, Lithium, Chlorpromazine
- Where
- Australia
- Volunteers
- 83 people
- Sponsor
- Melbourne Health